Advanced and emerging radiation therapy approaches for intrahepatic cholangiocarcinoma

Abstract

Radiotherapy (RT) is an integral component of the multidisciplinary care for intrahepatic cholangiocarcinoma (iCCA). Over the past decades, RT techniques have been developed with the aim of enhancing tumor control and minimizing toxicity. The most recent technological advancements include proton beam therapy (PBT) and magnetic resonance-guided radiotherapy (MRgRT). PBT is notable for its unique physical characteristics that allow for greater sparing of surrounding normal organs, especially the liver, from low to moderate doses of radiation. MRgRT provides advantages in other aspects, including superior tumor visualization before treatment, on-board treatment plan adaptation, and tumor tracking during treatment. These features allow for precise dose delivery and safe dose escalation, especially for patients with tumors close to luminal GI structures. In this review article, the rationale, clinical outcomes, clinical applications, challenges, and future directions of PBT and MRgRT are discussed. Additionally, the potential combination of novel therapeutics with RT in iCCA is explored.

Keywords

Adaptive radiotherapy / cholangiocarcinoma / intrahepatic cholangiocarcinoma / MR-guided radiotherapy / proton beam therapy / radiotherapy

References

[1] Rumgay H,de Martel C.Global, regional and national burden of primary liver cancer by subtype.Eur J Cancer2022;161:108-18.

[2] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88. PMCID:PMC7447603

[3] Primrose JN,Palmer DH.BILCAP study groupCapecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.Lancet Oncol2019;20:663-73.

[4] Zheng X,Wu JX.Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels.Cancer Manag Res2018;10:3973-81 PMCID:PMC6165777

[5] Jiang W,Tang ZY.Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases.J Cancer Res Clin Oncol2010;136:1323-31

[6] Sur MD,Sharpe SM.Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma.Ann Surg Oncol2015;22:2209-17.

[7] Lin YK,Wang WW.Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy.Radiother Oncol2018;128:575-83

[8] Shinohara ET,Guo M.Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.Int J Radiat Oncol Biol Phys2008;72:1495-501

[9] Kim YS,Go SI.The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas.Cancer Chemother Pharmacol2017;79:99-106

[10] Hammad AY,Eastwood D.Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? the impact of surgical margins and lymph node status on survival.Ann Surg Oncol2016;23:912-20

[11] Apisarnthanarax S,Cao M.External beam radiation therapy for primary liver cancers: an astro clinical practice guideline.Pract Radiat Oncol2022;12:28-51

[12] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[13] Oh D,Qin S.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.NEJM Evid2022;1:EVIDoa2200015

[14] Oh DY,Qin S.56P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC).Ann Oncol2022;33:S565-6

[15] Yamashita S,Passot G.Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients.Cancer2017;123:1354-62 PMCID:PMC5384875

[16] Valle JW,Nervi B,Zhu AX.Biliary tract cancer.Lancet2021;397:428-44

[17] Verma V,Lautenschlaeger T,Simone CB 2nd.Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.J Gastrointest Oncol2018;9:527-35 PMCID:PMC6006035

[18] Brunner TB,Lewitzki V.Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.Radiother Oncol2019;132:42-7.

[19] De B,Vauthey JN.Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care and survival in the United States.Cancer2022;128:2529-39 PMCID:PMC9177808

[20] Hong TS,Yeap BY.Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol2016;34:460-8 PMCID:PMC4872014

[21] Mahadevan A,Mancias J.Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma.J Cancer2015;6:1099-104. PMCID:PMC4615345

[22] Smart AC,Horick N.Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.Ann Surg Oncol2020;27:1122-9

[23] Tao R,Bhosale PR.Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis.J Clin Oncol2016;34:219-26 PMCID:PMC4980564

[24] Tse RV,Lockwood G.Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol2008;26:657-64

[25] Weiner AA,Ma D.Stereotactic body radiotherapy for primary hepatic malignancies-report of a phase I/II institutional study.Radiother Oncol2016;121:79-85. PMCID:PMC5543719

[26] Pascher A,Neuhaus P.Intrahepatic cholangiocarcinoma: indication for transplantation.J Hepatobiliary Pancreat Surg2003;10:282-7

[27] Chen X,Huang J,Yuan K.Neoadjuvant and adjuvant therapy in intrahepatic cholangiocarcinoma.J Clin Transl Hepatol2022;10:553-63. PMCID:PMC9240234

[28] Akateh C,Pawlik TM.Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.World J Hepatol2020;12:693-708 PMCID:PMC7643214

[29] Sumiyoshi T,Okabayashi T.Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma.World J Surg2018;42:2910-8.

[30] Cho Y,Seong J.Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma.Strahlenther Onkol2017;193:620-9

[31] Chuong MD,Khan F.Consensus report from the miami liver proton therapy conference.Front Oncol2019;9:457 PMCID:PMC6557299

[32] Wang X,Zhang X.Proton radiotherapy for liver tumors: dosimetric advantages over photon plans.Med Dosim2008;33:259-67.

[33] Petersen JB,Hansen AT,Grau C.Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours.Acta Oncol2011;50:823-8

[34] Engelsman M,Dong L.Physics controversies in proton therapy.Semin Radiat Oncol2013;23:88-96

[35] Makita C,Takada A.Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.Radiat Oncol2014;9:26. PMCID:PMC3904195

[36] Ohkawa A,Ishikawa H.Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.J Gastroenterol Hepatol2015;30:957-63.

[37] Shimizu S,Oshiro Y.Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy.Radiat Oncol2019;14:241 PMCID:PMC6935160

[38] Hung SP,Hsieh CE.Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy.Am J Clin Oncol2020;43:180-6.

[39] Kim TH,Lee WJ.Clinical efficacy of hypofractionated proton beam therapy for intrahepatic cholangiocarcinoma.Cancers2022;14:5561 PMCID:PMC9688899

[40] Tryggestad EJ,Pepin MD,Sio TT.Managing treatment-related uncertainties in proton beam radiotherapy for gastrointestinal cancers.J Gastrointest Oncol2020;11:212-24 PMCID:PMC7052758

[41] Bär E,Royle G,Bouchard H.The potential of dual-energy CT to reduce proton beam range uncertainties.Med Phys2017;44:2332-44

[42] Wroe AJ,Slater JD.Immobilization considerations for proton radiation therapy.Technol Cancer Res Treat2014;13:217-26

[43] Rietzel E.Respiratory motion management in particle therapy.Med Phys2010;37:449-60

[44] Liu W,Li Y.Robust optimization of intensity modulated proton therapy.Med Phys2012;39:1079-91 PMCID:PMC3281975

[45] Hu YH,Deiter NC.Analysis of the rate of re-planning in spot-scanning proton therapy.Int J Part Ther2022;9:49-58 PMCID:PMC9415746

[46] Lomax AJ.Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions.Phys Med Biol2008;53:1043-56

[47] Lomax AJ.Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties.Phys Med Biol2008;53:1027-42

[48] Bert C,Rietzel E.Quantification of interplay effects of scanned particle beams and moving targets.Phys Med Biol2008;53:2253-65

[49] Zhang Y,Tanner C,Knopf A.Respiratory liver motion estimation and its effect on scanned proton beam therapy.Phys Med Biol2012;57:1779-95

[50] De Ruysscher D,Haustermans K.Tumour movement in proton therapy: solutions and remaining questions: a review.Cancers2015;7:1143 PMCID:PMC4586762

[51] Lin B,Yang Y.FLASH radiotherapy: history and future.Front Oncol2021;11:644400 PMCID:PMC8185194

[52] Montay-Gruel P,Petersson K.Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species.Proc Natl Acad Sci USA2019;116:10943-51

[53] Vozenin MC,Petersson K.The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients.Clin Cancer Res2019;25:35-42.

[54] Favaudon V,Monceau V.Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.Sci Transl Med2014;6:245ra93

[55] Ruan JL,Wouters S.Irradiation at ultra-high (FLASH) dose rates reduces acute normal tissue toxicity in the mouse gastrointestinal system.Int J Radiat Oncol Biol Phys2021;111:1250-61 PMCID:PMC7612009

[56] Mascia AE,Zhang Y.Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial.JAMA Oncol2023;9:62-9 PMCID:PMC9589460

[57] Raaymakers BW,Overweg J.Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept.Phys Med Biol2009;54:N229-37.

[58] Mutic S.The viewray system: magnetic resonance-guided and controlled radiotherapy.Semin Radiat Oncol2014;24:196-9

[59] Raaymakers BW,Bol GH.First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment.Phys Med Biol2017;62:L41-50

[60] Rogowski P,Walter F.Feasibility and early clinical experience of online adaptive mr-guided radiotherapy of liver tumors.Cancers2021;13:1523 PMCID:PMC8037065

[61] Klüter S,Spindeldreier CK.First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany.Strahlenther Onkol2020;196:691-8 PMCID:PMC7385000

[62] Corradini S,Andratschke N.MR-guidance in clinical reality: current treatment challenges and future perspectives.Radiat Oncol2019;14:92 PMCID:PMC6551911

[63] Noel CE,Spencer CR.Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy.Acta Oncol2015;54:1474-82

[64] Kurz C,Landry G.Medical physics challenges in clinical MR-guided radiotherapy.Radiat Oncol2020;15:93 PMCID:PMC7201982

[65] Mittauer K,Hill P.A new era of image guidance with magnetic resonance-guided radiation therapy for abdominal and thoracic malignancies.Cureus2018;10:e2422 PMCID:PMC5985918

[66] Henke L,Robinson C.Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.Radiother Oncol2018;126:519-26.

[67] Feldman AM,Glide-Hurst C,Movsas B.Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-linac system.Cureus2019;11:e5774 PMCID:PMC6825488

[68] Luterstein E,Lamb JM.Clinical outcomes using magnetic resonance-guided stereotactic body radiation therapy in patients with locally advanced cholangiocarcinoma.Adv Radiat Oncol2019;5:189-95 PMCID:PMC7136637

[69] Rosenberg SA,Shaverdian N.A multi-institutional experience of mr-guided liver stereotactic body radiation therapy.Adv Radiat Oncol2019;4:142-9. PMCID:PMC6349638

[70] Chin RI,Bommireddy A.Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation therapy: a Six-Year experience.Clin Transl Radiat Oncol2023;41:100627. PMCID:PMC10334127

[71] Lamb J,Kishan A.Online adaptive radiation therapy: implementation of a new process of care.Cureus2017;9:e1618 PMCID:PMC5663325

[72] Hall WA,Li XA.Magnetic resonance linear accelerator technology and adaptive radiation therapy: an overview for clinicians.CA Cancer J Clin2022;72:34-56 PMCID:PMC8985054

[73] Witt JS,Bassetti MF.MRI-guided adaptive radiotherapy for liver tumours: visualising the future.Lancet Oncol2020;21:e74-82

[74] Ding J,Amjad A.Deep learning based automatic contour refinement for inaccurate auto-segmentation in MR-guided adaptive radiotherapy.Phys Med Biol2023;68:055004 PMCID:PMC9974902

[75] Güngör G,Temur B.Time analysis of online adaptive magnetic resonance-guided radiation therapy workflow according to anatomical sites.Pract Radiat Oncol2021;11:e11-21

[76] van Houdt PJ,van der Heide UA.Quantitative magnetic resonance imaging for biological image-guided adaptive radiotherapy.Front Oncol2020;10:615643. PMCID:PMC7878523

[77] Goyal L,Liu LY.TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.Cancer Discov2019;9:1064-79

[78] Javle M,Kelley RK.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol2021;6:803-15

[79] Abou-Alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020;21:671-84 PMCID:PMC8461541

[80] Goyal L,Hollebecque A.FOENIX-CCA2 Study InvestigatorsFutibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma.N Engl J Med2023;388:228-39

[81] Ahmed MA,Dörr W.Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.Oncotarget2016;7:69976-90. PMCID:PMC5342528

[82] Nuryadi E,Hagiwara Y.Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.Oncotarget2018;9:32642-52. PMCID:PMC6135691

[83] Yoshimoto Y,Murata K.Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.Gynecol Oncol2020;159:546-53.

[84] Ader I,Skuli N.Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.Eur J Cancer2014;50:2351-9

[85] Verstraete M,Gonnissen A.In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.BMC Cancer2015;15:946 PMCID:PMC4682227

[86] Boscoe AN,Kelley RK.Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.J Gastrointest Oncol2019;10:751-65 PMCID:PMC6657309

[87] Dang L,Gross S.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature2009;462:739-44 PMCID:PMC2818760

[88] Abou-Alfa GK,Javle MM.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020;21:796-807. PMCID:PMC7523268

[89] Tran AN,Li S.Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.Neuro Oncol2014;16:414-20 PMCID:PMC3922511

[90] Wang Y,Turcan S.Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.Sci Adv2020;6:eaaz3221 PMCID:PMC7176409

[91] FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [Last accessed on 15 Aug 2023]

[92] FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 15 Aug 2023]

[93] Silva VW,Daniel TD.Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.Chin Clin Oncol2016;5:62.

[94] Israel MA,McGregor KA.Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns.Oncologist2021;26:787-96 PMCID:PMC8417854

[95] Wang Y,Li N.Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions.Front Pharmacol2018;9:185 PMCID:PMC5844965

[96] Liu ZL,Peng H.Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report.Front Med2020;7:368. PMCID:PMC7485089

[97] Zhao Q,Du S.Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.Cancer Biol Ther2021;22:175-83 PMCID:PMC8043185

[98] Liu X,Song L,Huang T.Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.J Immunother Cancer2019;7:204 PMCID:PMC6683483

[99] Mondini M,Meziani L,Deutsch E.Radiotherapy-immunotherapy combinations-perspectives and challenges.Mol Oncol2020;14:1529-37. PMCID:PMC7332212